• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A


. 2023 Mar 28;120(13):e2300360120.
doi: 10.1073/pnas.2300360120. Epub 2023 Mar 20.
Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor


Kailu Yang[SUP] 1 2 3 4 5 [/SUP], Chuchu Wang[SUP] 1 2 3 4 5 [/SUP], Alex J B Kreutzberger[SUP] 6 7 [/SUP], K Ian White[SUP] 1 2 3 4 5 [/SUP], Richard A Pfuetzner[SUP] 1 2 3 4 5 [/SUP], Luis Esquivies[SUP] 1 2 3 4 5 [/SUP], Tomas Kirchhausen[SUP] 6 7 8 [/SUP], Axel T Brunger[SUP] 1 2 3 4 5 [/SUP]



Affiliations

Abstract

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) introduced a relatively large number of mutations, including three mutations in the highly conserved heptad repeat 1 (HR1) region of the spike glycoprotein (S) critical for its membrane fusion activity. We show that one of these mutations, N969K induces a substantial displacement in the structure of the heptad repeat 2 (HR2) backbone in the HR1HR2 postfusion bundle. Due to this mutation, fusion-entry peptide inhibitors based on the Wuhan strain sequence are less efficacious. Here, we report an Omicron-specific peptide inhibitor designed based on the structure of the Omicron HR1HR2 postfusion bundle. Specifically, we inserted an additional residue in HR2 near the Omicron HR1 K969 residue to better accommodate the N969K mutation and relieve the distortion in the structure of the HR1HR2 postfusion bundle it introduced. The designed inhibitor recovers the loss of inhibition activity of the original longHR2_42 peptide with the Wuhan strain sequence against the Omicron variant in both a cell-cell fusion assay and a vesicular stomatitis virus (VSV)-SARS-CoV-2 chimera infection assay, suggesting that a similar approach could be used to combat future variants. From a mechanistic perspective, our work suggests the interactions in the extended region of HR2 may mediate the initial landing of HR2 onto HR1 during the transition of the S protein from the prehairpin intermediate to the postfusion state.

Keywords: Omicron; SARS-CoV-2; inhibitor; membrane fusion; rational design.
 
Back
Top Bottom